Clinical Trial of Allogeneic Mesenchymal Stem Cell Therapy for Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients Unresponsive to Rituximab and Intravenous Immunoglobulin

Figure 4

Comparison of CD8+ T cell subsets before and after MSC treatment. PBMCs were stained with anti-CD8 APC-conjugated, anti-CD45RA ± FITC-conjugated, anti-CCR7 APC-conjugated, and anti-IFN-γ antibodies. CD8+ T cells were gated for further analysis. The proportions (%) of CD8+ T cells/lymphocytes, CD8+ Tnaive (CD45RA + CCR7+/CD8+ T cells), CD8+ TCM (CD45RA-CCR7+/CD8+ T cells), CD8+ TEM (CD45RA-CCR7-/CD8+ T cells), and CD8+ Tdiff (CD45RA + CCR7-/CD8+ T cells) in each patient were determined. After surface staining with anti-CD8 APC-conjugated, anti-CD45RA ± FITC-conjugated, and anti-CCR7 APC-conjugated antibodies, analysis of IFN-γ expression in CD8+ T cell subsets by intracellular flow cytometry was performed. The proportions (%) of IFN-γ+/CD8+ Tnaive (CD45RA + CCR7+/CD8+ T cells), IFN-γ+/CD8+ TCM (CD45RA-CCR7+/CD8+ T cells), IFN-γ+/CD8+ TEM (CD45RA-CCR7-/CD8+ T cells), and IFN-γ+/CD8+ Tdiff (CD45RA + CCR7-/CD8+ T cells) in each patient were determined. “Before” indicates the results at the start of MSC treatment, and “After” indicates the results at 3 months after the final MSC infusion. MSCs: mesenchymal stem cells; PBMCs: peripheral blood mononuclear cells.